You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCortisone acetate
Accession NumberDB01380
TypeSmall Molecule
GroupsApproved
DescriptionCortisone acetate is a steroid hormone that has both glucocoriticoid and mineral corticoid activities. Corticosteroids are used to provide relief for inflamed areas of the body. They lessen swelling, redness, itching, and allergic reactions. They are often used as part of the treatment for a number of different diseases, such as severe allergies or skin problems, asthma, or arthritis. Endogenous glucocorticoids and some synthetic corticoids have high affinity to the protein transcortin (also called CBG, corticosteroid-binding protein), whereas all of them bind albumin. Glucocorticoids also bind to the cytosolic glucocorticoid receptor.
Structure
Thumb
Synonyms
Cortisyl
Cortone acetate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cortisone Acetate Tab 25mgtablet25 mgoralValeant Canada Lp Valeant Canada S.E.C.1973-12-31Not applicableCanada
Cortone Sus 50mg/mlsuspension50 mgintramuscularMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1951-12-311999-08-06Canada
Cortone Tab 25mgtablet25 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1954-12-312002-07-29Canada
Cortone Tab 5mgtablet5 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1951-12-312002-07-29Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cortisone Acetatetablet25 mg/1oralWest ward Pharmaceutical Corp1972-06-13Not applicableUs
Cortisone Acetatetablet25 mg/1oralWest ward Pharmaceutical Corp2013-08-22Not applicableUs
Cortisone Acetatetablet25 mg/1oralHikma Pharmaceutical2013-08-26Not applicableUs
Cortisone Acetatetablet25 mg/1oralGolden State Medical Supply, Inc.1972-06-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Cortone Acetate MSD
Brand mixturesNot Available
SaltsNot Available
Categories
UNII883WKN7W8X
CAS number50-04-4
WeightAverage: 402.4807
Monoisotopic: 402.204238692
Chemical FormulaC23H30O6
InChI KeyInChIKey=ITRJWOMZKQRYTA-RFZYENFJSA-N
InChI
InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1
IUPAC Name
2-[(1S,2R,10S,11S,14R,15S)-14-hydroxy-2,15-dimethyl-5,17-dioxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl]-2-oxoethyl acetate
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • Oxosteroid
  • 11-oxosteroid
  • Hydroxysteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Alpha-acyloxy ketone
  • Cyclohexanone
  • Acetate salt
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Ketone
  • Carboxylic acid ester
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
  • C21 steroids (gluco/mineralocorticoids, progestogens) and derivatives (C08173 )
  • C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030120 )
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders.
PharmacodynamicsAs a glucocorticoid agent, cortisone acetate changes genetic transcription levels causing varied metabolic effects and a modified immune response to varied stimuli. lucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.
Mechanism of actionCortisone acetate binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationCorticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects include inhibition of bone formation, suppression of calcium absorption, delayed wound healing and hyperglycemia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.983
Blood Brain Barrier+0.9851
Caco-2 permeable-0.6606
P-glycoprotein substrateSubstrate0.7382
P-glycoprotein inhibitor IInhibitor0.7341
P-glycoprotein inhibitor IIInhibitor0.5925
Renal organic cation transporterNon-inhibitor0.7452
CYP450 2C9 substrateNon-substrate0.8551
CYP450 2D6 substrateNon-substrate0.9294
CYP450 3A4 substrateSubstrate0.7841
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9556
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8588
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9246
Ames testNon AMES toxic0.9409
CarcinogenicityNon-carcinogens0.9551
BiodegradationNot ready biodegradable0.9354
Rat acute toxicity2.1280 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9599
hERG inhibition (predictor II)Non-inhibitor0.6638
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral25 mg/1
Tabletoral25 mg
Suspensionintramuscular50 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Cortisone acetate powder24.18USD g
Cortisone Acetate 25 mg Tablet0.47USD tablet
Cortisone 25 mg tablet0.46USD tablet
Cortaid 1% cream0.21USD g
CVS Pharmacy cortisone 1% cream0.18USD g
CVS Pharmacy anti-itch 1% cream0.13USD g
Hydrocortisone 0.5% cream0.11USD g
Medi-cortisone 1% cream0.1USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point227-229Reichstein,T.; US. Patent 2,403,683; July 9, 1946. Gallagher,T.F.; US. Patent 2,447,325; August 17,1948; assigned to Research Corporation. Sarett, L.H.; U.S. Patent 2,541,104; February 13, 1951; assigned to Merck & Co., Inc.
water solubility20 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.10HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0278 mg/mLALOGPS
logP2.35ALOGPS
logP2.1ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)12.6ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area97.74 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity105.63 m3·mol-1ChemAxon
Polarizability43.25 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Reichstein,T.; US. Patent 2,403,683; July 9, 1946.
Gallagher,T.F.; US. Patent 2,447,325; August 17,1948; assigned to Research Corporation.
Sarett, L.H.; U.S. Patent 2,541,104; February 13, 1951; assigned to Merck & Co., Inc.

General ReferencesNot Available
External Links
ATC CodesH02AB10S01BA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.3 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with 1,10-Phenanthroline.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Cortisone acetate.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Cortisone acetate.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Cortisone acetate.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Cortisone acetate.
AldesleukinCortisone acetate may decrease the antineoplastic activities of Aldesleukin.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Cortisone acetate.
Aluminum hydroxideThe bioavailability of Cortisone acetate can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Cortisone acetate can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Cortisone acetate.
AmiodaroneThe serum concentration of Cortisone acetate can be increased when it is combined with Amiodarone.
Amphotericin BCortisone acetate may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Cortisone acetate can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Cortisone acetate can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Cortisone acetate can be decreased when combined with Atomoxetine.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Cortisone acetate.
BazedoxifeneThe serum concentration of Cortisone acetate can be increased when it is combined with Bazedoxifene.
BendroflumethiazideCortisone acetate may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Cortisone acetate.
BexaroteneThe serum concentration of Cortisone acetate can be decreased when it is combined with Bexarotene.
Bismuth SubcitrateThe bioavailability of Cortisone acetate can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Cortisone acetate can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Cortisone acetate can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Cortisone acetate can be decreased when it is combined with Bosentan.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Cortisone acetate.
BumetanideCortisone acetate may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Cortisone acetate.
Calcium carbonateThe bioavailability of Cortisone acetate can be decreased when combined with Calcium carbonate.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cortisone acetate.
CarbamazepineThe serum concentration of Cortisone acetate can be decreased when it is combined with Carbamazepine.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Cortisone acetate.
CeritinibThe serum concentration of Cortisone acetate can be increased when it is combined with Ceritinib.
CeritinibCortisone acetate may increase the hyperglycemic activities of Ceritinib.
ChlorothiazideCortisone acetate may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Cortisone acetate can be increased when it is combined with Chlorotrianisene.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cortisone acetate.
ChlorthalidoneCortisone acetate may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Cortisone acetate.
ClarithromycinThe serum concentration of Cortisone acetate can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Cortisone acetate can be decreased when combined with Clemastine.
ClotrimazoleThe metabolism of Cortisone acetate can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Cortisone acetate can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Cortisone acetate can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Cortisone acetate can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Cortisone acetate.
CoumaphosThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Coumaphos.
CrizotinibThe metabolism of Cortisone acetate can be decreased when combined with Crizotinib.
CyclosporineThe metabolism of Cortisone acetate can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Cortisone acetate can be decreased when it is combined with Dabrafenib.
DarunavirThe serum concentration of Cortisone acetate can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Cortisone acetate can be increased when it is combined with Dasatinib.
DecamethoniumThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Decamethonium.
DeferasiroxThe serum concentration of Cortisone acetate can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Deferasirox.
DelavirdineThe metabolism of Cortisone acetate can be decreased when combined with Delavirdine.
DemecariumThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Demecarium.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cortisone acetate.
DexamethasoneThe serum concentration of Cortisone acetate can be decreased when it is combined with Dexamethasone.
DichlorvosThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Dichlorvos.
DienestrolThe serum concentration of Cortisone acetate can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Cortisone acetate can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cortisone acetate.
DihydroergotamineThe metabolism of Cortisone acetate can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneCortisone acetate may increase the fluid retaining activities of Dihydrotestosterone.
DiltiazemThe metabolism of Cortisone acetate can be decreased when combined with Diltiazem.
DonepezilThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Donepezil.
DoxycyclineThe metabolism of Cortisone acetate can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Cortisone acetate can be decreased when combined with Dronedarone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Cortisone acetate.
EchothiophateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Edrophonium.
EfavirenzThe serum concentration of Cortisone acetate can be decreased when it is combined with Efavirenz.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cortisone acetate.
EnzalutamideThe serum concentration of Cortisone acetate can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Cortisone acetate can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Cortisone acetate can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Cortisone acetate can be increased when it is combined with Estriol.
EstroneThe serum concentration of Cortisone acetate can be increased when it is combined with Estrone.
Etacrynic acidCortisone acetate may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Cortisone acetate can be increased when it is combined with Ethinyl Estradiol.
EtravirineThe serum concentration of Cortisone acetate can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Cortisone acetate.
FenthionThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Fenthion.
FingolimodCortisone acetate may increase the immunosuppressive activities of Fingolimod.
FluconazoleThe metabolism of Cortisone acetate can be decreased when combined with Fluconazole.
FluoxymesteroneCortisone acetate may increase the fluid retaining activities of Fluoxymesterone.
FluvoxamineThe metabolism of Cortisone acetate can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Cortisone acetate can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Cortisone acetate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Cortisone acetate can be decreased when it is combined with Fosphenytoin.
FurosemideCortisone acetate may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Cortisone acetate can be increased when it is combined with Fusidic Acid.
GalantamineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Cortisone acetate can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ginkgo biloba.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Cortisone acetate.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Cortisone acetate.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Cortisone acetate.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Cortisone acetate.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Cortisone acetate.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cortisone acetate.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Cortisone acetate.
HexestrolThe serum concentration of Cortisone acetate can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cortisone acetate.
HydrochlorothiazideCortisone acetate may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideCortisone acetate may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Cortisone acetate can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Cortisone acetate can be decreased when combined with Imatinib.
IndacaterolIndacaterol may increase the hypokalemic activities of Cortisone acetate.
IndapamideCortisone acetate may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Cortisone acetate can be increased when it is combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Cortisone acetate.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Cortisone acetate.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Cortisone acetate.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Cortisone acetate.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Cortisone acetate.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Cortisone acetate.
IsavuconazoniumThe metabolism of Cortisone acetate can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Cortisone acetate.
IsradipineThe metabolism of Cortisone acetate can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Cortisone acetate can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Cortisone acetate can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Cortisone acetate can be increased when it is combined with Ketoconazole.
LeflunomideThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Leflunomide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Cortisone acetate.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Cortisone acetate.
LopinavirThe serum concentration of Cortisone acetate can be increased when it is combined with Lopinavir.
LovastatinThe metabolism of Cortisone acetate can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Cortisone acetate can be increased when it is combined with Luliconazole.
MagaldrateThe bioavailability of Cortisone acetate can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Cortisone acetate.
MestranolThe serum concentration of Cortisone acetate can be increased when it is combined with Mestranol.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Cortisone acetate.
MethyclothiazideCortisone acetate may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneCortisone acetate may increase the fluid retaining activities of Methyltestosterone.
MetolazoneCortisone acetate may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Cortisone acetate.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Cortisone acetate.
MinaprineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Minaprine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Cortisone acetate.
MitotaneThe serum concentration of Cortisone acetate can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Cortisone acetate.
ModafinilThe serum concentration of Cortisone acetate can be decreased when it is combined with Modafinil.
NafcillinThe serum concentration of Cortisone acetate can be decreased when it is combined with Nafcillin.
NatalizumabThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Natalizumab.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Cortisone acetate.
NefazodoneThe serum concentration of Cortisone acetate can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Cortisone acetate can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Neostigmine.
NetupitantThe serum concentration of Cortisone acetate can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Cortisone acetate can be decreased when combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Nicorandil.
NilotinibThe metabolism of Cortisone acetate can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cortisone acetate.
OlaparibThe metabolism of Cortisone acetate can be decreased when combined with Olaparib.
OsimertinibThe serum concentration of Cortisone acetate can be increased when it is combined with Osimertinib.
OxandroloneCortisone acetate may increase the fluid retaining activities of Oxandrolone.
OxymetholoneCortisone acetate may increase the fluid retaining activities of Oxymetholone.
PalbociclibThe serum concentration of Cortisone acetate can be increased when it is combined with Palbociclib.
PentobarbitalThe serum concentration of Cortisone acetate can be decreased when it is combined with Pentobarbital.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Cortisone acetate.
PhenobarbitalThe serum concentration of Cortisone acetate can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Cortisone acetate.
PhenytoinThe serum concentration of Cortisone acetate can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Physostigmine.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cortisone acetate.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Cortisone acetate.
PiretanideCortisone acetate may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Cortisone acetate can be increased when it is combined with Polyestradiol phosphate.
PolythiazideCortisone acetate may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Cortisone acetate can be increased when it is combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Cortisone acetate.
PrimidoneThe serum concentration of Cortisone acetate can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pyridostigmine.
QuinestrolThe serum concentration of Cortisone acetate can be increased when it is combined with Quinestrol.
QuinethazoneCortisone acetate may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rabies vaccine.
RanolazineThe metabolism of Cortisone acetate can be decreased when combined with Ranolazine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Cortisone acetate.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Cortisone acetate.
RifabutinThe serum concentration of Cortisone acetate can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Cortisone acetate can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Cortisone acetate can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Cortisone acetate can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rivastigmine.
RoflumilastRoflumilast may increase the immunosuppressive activities of Cortisone acetate.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Cortisone acetate.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Cortisone acetate.
SaquinavirThe serum concentration of Cortisone acetate can be increased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Cortisone acetate.
SildenafilThe metabolism of Cortisone acetate can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Cortisone acetate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Cortisone acetate can be increased when it is combined with Simeprevir.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cortisone acetate.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Cortisone acetate.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Cortisone acetate.
Somatropin recombinantThe therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Somatropin recombinant.
St. John's WortThe serum concentration of Cortisone acetate can be decreased when it is combined with St. John's Wort.
StanozololCortisone acetate may increase the fluid retaining activities of Stanozolol.
StiripentolThe serum concentration of Cortisone acetate can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Cortisone acetate can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Cortisone acetate.
Synthetic Conjugated Estrogens, AThe serum concentration of Cortisone acetate can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Cortisone acetate can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cortisone acetate.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Cortisone acetate.
TelaprevirThe serum concentration of Cortisone acetate can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Cortisone acetate can be increased when it is combined with Telithromycin.
TesamorelinThe serum concentration of the active metabolites of Cortisone acetate can be reduced when Cortisone acetate is used in combination with Tesamorelin resulting in a loss in efficacy.
TestosteroneCortisone acetate may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Cortisone acetate can be increased when it is combined with Tibolone.
TiclopidineThe metabolism of Cortisone acetate can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Cortisone acetate can be decreased when it is combined with Tocilizumab.
TofacitinibCortisone acetate may increase the immunosuppressive activities of Tofacitinib.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Cortisone acetate.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Cortisone acetate.
TorasemideCortisone acetate may increase the hypokalemic activities of Torasemide.
TrastuzumabTrastuzumab may increase the neutropenic activities of Cortisone acetate.
TrichlorfonThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Trichlorfon.
TrichlormethiazideCortisone acetate may increase the hypokalemic activities of Trichlormethiazide.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Cortisone acetate.
TubocurarineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Tubocurarine.
VenlafaxineThe metabolism of Cortisone acetate can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Cortisone acetate can be decreased when combined with Verapamil.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Cortisone acetate.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Cortisone acetate.
VoriconazoleThe serum concentration of Cortisone acetate can be increased when it is combined with Voriconazole.
WarfarinCortisone acetate may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Cortisone acetate can be increased when it is combined with Zeranol.
ZiprasidoneThe metabolism of Cortisone acetate can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  2. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953 ]
  3. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198 ]
  4. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445 ]
  5. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345 ]
  6. Schlechte JA, Ginsberg BH, Sherman BM: Regulation of the glucocorticoid receptor in human lymphocytes. J Steroid Biochem. 1982 Jan;16(1):69-74. [PubMed:7062741 ]
  7. Schlechte JA, Sherman BM: Decreased glucocorticoid receptor binding in adrenal insufficiency. J Clin Endocrinol Metab. 1982 Jan;54(1):145-9. [PubMed:7054210 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on July 06, 2007 14:32 / Updated on August 19, 2016 10:26